Manufacturing building used in the manufacture ofAVANCE does not have the adequate controls to prevent contamination.
Inspection Record
Axogen Corporation — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Environmental monitoring program is deficient to ensure classified environments.
Procedures describing the warehousing ofAVANCE final product, printed product labels, and retain samples are not established.
Investigations into pest control deviations are deficient.
Deviation management is inadequate to demonstrate quality oversight ofthe manufacturing process.
Laboratory controls are not adequately established and do not include scientifically sound test procedures and sampling plans designed to assure that AVANCE drug product conform to appropriate standards of identity, strength, quality, and purity.
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.